Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GSK3377794 with or without pembrolizumab in HLA-A2 positive NY-ESO-1/LAGE-1a positive advanced non-small cell lung cancer
NL-OMON52531Phase 2Completed
- Sponsor
- GSK
- Start
- Feb 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of letetresgene autoleucel and pembrolizumab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by GSK. Primary endpoints: Adverse events, ECOG performance status and 1 more. Started Feb 2020; status: completed.
02
Drugs
letetresgene autoleucelpembrolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON52531.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52531.